schliessen

Filtern

 

Bibliotheken

Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.

PURPOSEWe studied the ablative activity of intravesical apaziquone (EOquin) on a papillary marker tumor and determined the incidence of side effects. MATERIALS AND METHODSA total of 46 patients with multiple pTa or pT1 bladder tumors underwent visible lesion resection except for 1 marker tumor. Pati... Full description

Journal Title: The Journal of urology October 2006, Vol.176(4 Pt 1), pp.1349-53; discussion 1353
Main Author: van Der Heijden, Antoine G
Other Authors: Moonen, Paula M J , Cornel, Erik B , Vergunst, Henk , de Reijke, Theo M , van Boven, Erika , Barten, Evert J , Puri, Rajiv , van Kalken, Coenraad K , Witjes, J Alfred
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0022-5347
Link: http://search.proquest.com/docview/68835150/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest68835150
title: Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.
format: Article
creator:
  • van Der Heijden, Antoine G
  • Moonen, Paula M J
  • Cornel, Erik B
  • Vergunst, Henk
  • de Reijke, Theo M
  • van Boven, Erika
  • Barten, Evert J
  • Puri, Rajiv
  • van Kalken, Coenraad K
  • Witjes, J Alfred
subjects:
  • Administration, Intravesical–Administration & Dosage
  • Adult–Adverse Effects
  • Aged–Administration & Dosage
  • Aged, 80 and Over–Adverse Effects
  • Antineoplastic Agents–Drug Therapy
  • Aziridines–Pathology
  • Carcinoma, Transitional Cell–Administration & Dosage
  • Cohort Studies–Adverse Effects
  • Dose-Response Relationship, Drug–Drug Therapy
  • Drug Administration Schedule–Pathology
  • Female–Pathology
  • Humans–Pathology
  • Indolequinones–Pathology
  • Male–Pathology
  • Middle Aged–Pathology
  • Treatment Outcome–Pathology
  • Urinary Bladder Neoplasms–Pathology
  • Abridged
  • Antineoplastic Agents
  • Aziridines
  • Indolequinones
  • Apaziquone
ispartof: The Journal of urology, October 2006, Vol.176(4 Pt 1), pp.1349-53; discussion 1353
description: PURPOSEWe studied the ablative activity of intravesical apaziquone (EOquin) on a papillary marker tumor and determined the incidence of side effects. MATERIALS AND METHODSA total of 46 patients with multiple pTa or pT1 bladder tumors underwent visible lesion resection except for 1 marker tumor. Patients were then treated with 6 instillations of apaziquone at weekly intervals. The response was determined 2 to 4 weeks after the last instillation. RESULTSOne patient withdrew informed consent and refused the last treatment due to side effects. A histologically proven complete response was seen in 30 patients. Progression to invasive stage was not observed. Local side effects in this study were comparable to those due to other chemotherapy instillations, such as mitomycin C and epirubicin, but less severe and less frequent compared to those of bacillus Calmette-Guerin instillations. CONCLUSIONSThe histological complete response rate after 6 consecutive instillations of apaziquone in patients with superficial bladder cancer was 67% (95% CI 51 to 80). Local side effects were comparable to side effects due to other chemotherapy instillations.
language: eng
source:
identifier: ISSN: 0022-5347
fulltext: fulltext
issn:
  • 00225347
  • 0022-5347
url: Link


@attributes
ID1719283800
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid68835150
sourceidproquest
recordidTN_proquest68835150
sourcesystemOther
pqid68835150
galeid196260244
display
typearticle
titlePhase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.
creatorvan Der Heijden, Antoine G ; Moonen, Paula M J ; Cornel, Erik B ; Vergunst, Henk ; de Reijke, Theo M ; van Boven, Erika ; Barten, Evert J ; Puri, Rajiv ; van Kalken, Coenraad K ; Witjes, J Alfred
contributorvan Der Heijden, Antoine G (correspondence author) ; van Der Heijden, Antoine G (record owner)
ispartofThe Journal of urology, October 2006, Vol.176(4 Pt 1), pp.1349-53; discussion 1353
identifierISSN: 0022-5347
subjectAdministration, Intravesical–Administration & Dosage ; Adult–Adverse Effects ; Aged–Administration & Dosage ; Aged, 80 and Over–Adverse Effects ; Antineoplastic Agents–Drug Therapy ; Aziridines–Pathology ; Carcinoma, Transitional Cell–Administration & Dosage ; Cohort Studies–Adverse Effects ; Dose-Response Relationship, Drug–Drug Therapy ; Drug Administration Schedule–Pathology ; Female–Pathology ; Humans–Pathology ; Indolequinones–Pathology ; Male–Pathology ; Middle Aged–Pathology ; Treatment Outcome–Pathology ; Urinary Bladder Neoplasms–Pathology ; Abridged ; Antineoplastic Agents ; Aziridines ; Indolequinones ; Apaziquone
descriptionPURPOSEWe studied the ablative activity of intravesical apaziquone (EOquin) on a papillary marker tumor and determined the incidence of side effects. MATERIALS AND METHODSA total of 46 patients with multiple pTa or pT1 bladder tumors underwent visible lesion resection except for 1 marker tumor. Patients were then treated with 6 instillations of apaziquone at weekly intervals. The response was determined 2 to 4 weeks after the last instillation. RESULTSOne patient withdrew informed consent and refused the last treatment due to side effects. A histologically proven complete response was seen in 30 patients. Progression to invasive stage was not observed. Local side effects in this study were comparable to those due to other chemotherapy instillations, such as mitomycin C and epirubicin, but less severe and less frequent compared to those of bacillus Calmette-Guerin instillations. CONCLUSIONSThe histological complete response rate after 6 consecutive instillations of apaziquone in patients with superficial bladder cancer was 67% (95% CI 51 to 80). Local side effects were comparable to side effects due to other chemotherapy instillations.
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/68835150/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0van Der Heijden, Antoine G
1Moonen, Paula M J
2Cornel, Erik B
3Vergunst, Henk
4de Reijke, Theo M
5van Boven, Erika
6Barten, Evert J
7Puri, Rajiv
8van Kalken, Coenraad K
9Witjes, J Alfred
titlePhase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.
descriptionPURPOSEWe studied the ablative activity of intravesical apaziquone (EOquin) on a papillary marker tumor and determined the incidence of side effects. MATERIALS AND METHODSA total of 46 patients with multiple pTa or pT1 bladder tumors underwent visible lesion resection except for 1 marker tumor. Patients were then treated with 6 instillations of apaziquone at weekly intervals. The response was determined 2 to 4 weeks after the last instillation. RESULTSOne patient withdrew informed consent and refused the last treatment due to side effects. A histologically proven complete response was seen in 30 patients. Progression to invasive stage was not observed. Local side effects in this study were comparable to those due to other chemotherapy instillations, such as mitomycin C and epirubicin, but less severe and less frequent compared to those of bacillus Calmette-Guerin instillations. CONCLUSIONSThe histological complete response rate after 6 consecutive instillations of apaziquone in patients with superficial bladder cancer was 67% (95% CI 51 to 80). Local side effects were comparable to side effects due to other chemotherapy instillations.
subject
0Administration, Intravesical–Administration & Dosage
1Adult–Adverse Effects
2Aged–Administration & Dosage
3Aged, 80 and Over–Adverse Effects
4Antineoplastic Agents–Drug Therapy
5Aziridines–Pathology
6Carcinoma, Transitional Cell–Administration & Dosage
7Cohort Studies–Adverse Effects
8Dose-Response Relationship, Drug–Drug Therapy
9Drug Administration Schedule–Pathology
10Female–Pathology
11Humans–Pathology
12Indolequinones–Pathology
13Male–Pathology
14Middle Aged–Pathology
15Treatment Outcome–Pathology
16Urinary Bladder Neoplasms–Pathology
17Abridged
18Antineoplastic Agents
19Aziridines
20Indolequinones
21Apaziquone
general
0English
1MEDLINE (ProQuest)
2ProQuest Biological Science Collection
3ProQuest Environmental Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Agricultural & Environmental Science Database
7Biological Science Database
8Natural Science Collection
9SciTech Premium Collection
10Health Research Premium Collection
11Health Research Premium Collection (Alumni edition)
sourceidproquest
recordidproquest68835150
issn
000225347
10022-5347
rsrctypearticle
creationdate2006
addtitleThe Journal of urology
searchscope
01007489
11007527
21007944
310000004
410000006
510000038
610000043
710000050
810000120
910000159
1010000198
1110000200
1210000209
1310000217
1410000234
1510000238
1610000253
1710000260
1810000270
1910000271
2010000302
21proquest
scope
01007489
11007527
21007944
310000004
410000006
510000038
610000043
710000050
810000120
910000159
1010000198
1110000200
1210000209
1310000217
1410000234
1510000238
1610000253
1710000260
1810000270
1910000271
2010000302
21proquest
lsr43
01007489false
11007527false
21007944false
310000004false
410000006false
510000038false
610000043false
710000050false
810000120false
910000159false
1010000198false
1110000200false
1210000209false
1310000217false
1410000234false
1510000238false
1610000253false
1710000260false
1810000270false
1910000271false
2010000302false
contributorvan Der Heijden, Antoine G
startdate20061001
enddate20061001
citationpf 1349 pt 53; discussion 1353 vol 176 issue 4 Pt 1
lsr30VSR-Enriched:[eissn, issue, pqid, pages, galeid, doi]
sort
titlePhase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.
authorvan Der Heijden, Antoine G ; Moonen, Paula M J ; Cornel, Erik B ; Vergunst, Henk ; de Reijke, Theo M ; van Boven, Erika ; Barten, Evert J ; Puri, Rajiv ; van Kalken, Coenraad K ; Witjes, J Alfred
creationdate20061001
lso0120061001
facets
frbrgroupid9174645757624635363
frbrtype5
newrecords20181218
languageeng
creationdate2006
topic
0Administration, Intravesical–Administration & Dosage
1Adult–Adverse Effects
2Aged–Administration & Dosage
3Aged, 80 and Over–Adverse Effects
4Antineoplastic Agents–Drug Therapy
5Aziridines–Pathology
6Carcinoma, Transitional Cell–Administration & Dosage
7Cohort Studies–Adverse Effects
8Dose-Response Relationship, Drug–Drug Therapy
9Drug Administration Schedule–Pathology
10Female–Pathology
11Humans–Pathology
12Indolequinones–Pathology
13Male–Pathology
14Middle Aged–Pathology
15Treatment Outcome–Pathology
16Urinary Bladder Neoplasms–Pathology
17Abridged
18Antineoplastic Agents
19Aziridines
20Indolequinones
21Apaziquone
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Environmental Science Collection
3ProQuest Natural Science Collection
4ProQuest SciTech Collection
5Agricultural & Environmental Science Database
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
prefilterarticles
rsrctypearticles
creatorcontrib
0van Der Heijden, Antoine G
1Moonen, Paula M J
2Cornel, Erik B
3Vergunst, Henk
4de Reijke, Theo M
5van Boven, Erika
6Barten, Evert J
7Puri, Rajiv
8van Kalken, Coenraad K
9Witjes, J Alfred
jtitleJournal of urology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0van der Heijden
1Moonen
2Cornel
3Vergunst
4de Reijke
5van Boven
6Barten
7Puri
8van Kalken
9Witjes
aufirst
0Antoine G
1Paula M J
2Erik B
3Henk
4Theo M
5Erika
6Evert J
7Rajiv
8Coenraad K
9J Alfred
au
0van Der Heijden, Antoine G
1Moonen, Paula M J
2Cornel, Erik B
3Vergunst, Henk
4de Reijke, Theo M
5van Boven, Erika
6Barten, Evert J
7Puri, Rajiv
8van Kalken, Coenraad K
9Witjes, J Alfred
addauvan der Heijden, Antoine G
atitlePhase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.
jtitleThe Journal of urology
risdate20061001
volume176
issue4
spage1349
epage53; discussion 1353
pages1349-1353
issn0022-5347
formatjournal
genrearticle
ristypeJOUR
abstractPURPOSEWe studied the ablative activity of intravesical apaziquone (EOquin) on a papillary marker tumor and determined the incidence of side effects. MATERIALS AND METHODSA total of 46 patients with multiple pTa or pT1 bladder tumors underwent visible lesion resection except for 1 marker tumor. Patients were then treated with 6 instillations of apaziquone at weekly intervals. The response was determined 2 to 4 weeks after the last instillation. RESULTSOne patient withdrew informed consent and refused the last treatment due to side effects. A histologically proven complete response was seen in 30 patients. Progression to invasive stage was not observed. Local side effects in this study were comparable to those due to other chemotherapy instillations, such as mitomycin C and epirubicin, but less severe and less frequent compared to those of bacillus Calmette-Guerin instillations. CONCLUSIONSThe histological complete response rate after 6 consecutive instillations of apaziquone in patients with superficial bladder cancer was 67% (95% CI 51 to 80). Local side effects were comparable to side effects due to other chemotherapy instillations.
urlhttp://search.proquest.com/docview/68835150/
doi10.1016/j.juro.2006.06.007
eissn15273792
date2006-10-01